Development of sunitinib in the treatment of imatinib-resistant gastrointestinal stromal tumors
10.3760/cma.j.issn.1673-4203.2011.02.018
- VernacularTitle:舒尼替尼治疗耐伊马替尼胃肠道间质瘤的研究进展
- Author:
Ke WANG
;
Kefeng DING
- Publication Type:Journal Article
- Keywords:
Sunitinib;
Gastrointestinal stromal tumors;
Resistance
- From:
International Journal of Surgery
2011;38(2):132-135
- CountryChina
- Language:Chinese
-
Abstract:
Sunitinib malate (SU11248 ,Sutent) is an orally available small-molecule multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities.In 2006 sunitinib was approved by FDA for imatinib intolerant gastrointestinal stromal tumors (GIST) patients or imatinib resistant GIST patients.This article review the molecular-based mechanism,the mechanism of resistance,the biomarker,the clinical trials and the adverse effects of sunitinib in the treatment of imatinib-resistant GIST.